News

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

New 48-month results from the phase 3 extension also showed greater macula and retina preservation in patients treated earlier.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

This study demonstrates the impact of an elastic scattering spectroscopy (ESS) device, owned by DermaSensor, on melanoma assessment in primary care settings.

This preview of the 2025 NASPGHAN Annual Meeting highlights sessions and expert discussions on pediatric gastroenterology, hepatology, and nutrition covered by HCPLive.

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

Yu describes factors delaying EoE diagnosis and breaks down ways to improve diagnosis and care based on findings from her quality improvement initiative.

The decision makes linaclotide (Linzess) capsules the first FDA-approved treatment for pediatric patients 7 years and older with irritable bowel syndrome with constipation.

This preview of the 2025 SDPA Fall Dermatology Conference highlights different sessions and interviews covered by HCPLive.

A preview of 5 slated expert interviews and 5 late-breaking clinical trials to watch out for at ACAAI 2025.

Catch up on the groundbreaking FDA approvals, key trial updates, and more news from the last month.

ABBV-CLS-628, an anti–PAPP-A monoclonal antibody, earns Orphan Drug Designation, advancing through phase 2 testing for ADPKD.

View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Afzali details GALAXI post hoc findings on guselkumab in Crohn’s disease.

This month in review spotlights 6 top allergy stories, from falling peanut allergy rates to intranasal steroid cream easing post-surgical rhinosinusitis.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

Check out the latest GI FDA news, new trial data in IBD, headlines from ACG 2025, and more.

October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs

Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.

In this review of the month of October, HCPLive highlights some of the most significant dermatology news updates.